Dr HepoganGod 2023 - Prevent Hepa B

💥 [Attention Philippines] Ang pinakabagong paggamot sa hepatitis B ay magagamit, 96 beses na mas epektibo kaysa sa mga tradisyonal na pamamaraan >> https://st1.drhepogangold2022.com/
👉Panoorin ang buong video (1 minuto) para matutunan kung paano ligtas na maibalik ang iyong atay.
----------------------------
❌Kung nahaharap ka sa mga problema sa ibaba:
- Dilaw na balat, dilaw na mata
- Pantal sa balat
- pananakit ng tiyan, utot
- Ang paggamot sa loob ng maraming taon ay hindi bumuti
🔰 2 capsules lang kada araw sa bahay:
- Hindi na kailangang pumunta sa ospital
- Epektibo pagkatapos ng 7-10 araw ng paggamit
- Kahit sino ay maaaring gumamit nito
🙏Dr.HepoganGold ay nakatuon sa mga customer
- I-refund kung nakatanggap ng mga pekeng kalakal
- Libreng pagpapadala
- Ang produkto ay sertipikado ng Ministry of Health
- Tumanggap ng mga kalakal pagkatapos ng 5-7 araw, direktang magbayad ng cash
🌐 Ang aming website ay naglalaman ng kumpletong impormasyon tungkol sa mga produkto at presyo.
👉I-click ang link para sa agarang pag-access >>> https://st1.drhepogangold2022.com/

“ IBINAHAGI NI DR.HEPOGAN GOLD ANG SIKRETO: PAGGAMOT NG TALAMAK NA HEPATITIS B - PAGBABAWAS NG PANINILAW NG MGA MATA, PAG-ALIS NG PANANAKIT NG TIYAN, PANGANGATI, PAGKAPAGOD NG KATAWAN - PAG-IWAS SA MGA VIRUS - PAG-IWAS SA MGA KOMPLIKASYON."
--------------
+) Treatment of chronic hepatitis B
+) Reduces yellowing of the skin and eyes, abdominal pain, itching, body fatigue
+) Prevention of hepatitis B virus
+) Prevention of complications.
ONLY OFFER FOR FIRST 199 CUSTOMERS:
40% OFF ORDER VALUE:
- Buy 5 get 3 free
- Buy 4 get 2 free
- Buy 2 get 1 free
- Buy 10 boxes for wholesale price
-------------------------
Quickly MESSAGE, leave your phone number >> FREE CONSULTATION
Consulting call center: https://st1.drhepogangold2022.com/
Leave your phone number >> SELF PRICE

💥Libo-libong regalo para sa mga customer na umorder ng Dr HepoganGold sa livestream na ito
Buy 5 get 3; Buy 3 get 2; Buy 2 get 1 👇
Kunin ang iyong regalo dito: https://st1.drhepogangold2022.com/
------------
👉 Kontrolin ang antas ng hepatitis B virus sa isang ligtas na antas, bawasan ang panganib ng mga komplikasyon, pagbutihin ang paggana ng atay, pagpapanumbalik ng mga nasirang selula ng atay
✅ Mga oral tablet para sa talamak na hepatitis B Dr HepoganGold na may mahahalagang essences tulad ng Silymarin, Solanum procumbens, Phyllanthaceae, Curcumin:
- Sinusuportahan ang pagbawi ng function ng atay, pinipigilan ang hepatitis B virus mula sa pag-atake sa mga selula ng atay, pinoprotektahan ang atay mula sa loob mula sa alkohol at mga nakakapinsalang pagkain.
- Tumutulong upang mabilis na mapawi ang mga sintomas ng dilaw na balat, dilaw na mata, pagkapagod, pagduduwal, pananakit ng tiyan, pantal, pagkapagod ng katawan
✅ Precious essence 100% from nature, imported and applied the number 1 modern essence technology from Korea to increase absorption, absolute safety and high efficiency.
- Ang produkto ay madaling inumin, madaling matunaw, maginhawang dalhin kahit saan, anumang oras
- Uminom ng 1 tablet x 2 beses sa isang araw, 1 tablet sa umaga, 1 tablet sa gabi, 30 minuto pagkatapos kumain
✅ Ang produkto ay nasubok at na-certify ng Ministry of Health
-------------
👉 Get a quote here: https://st1.drhepogangold2022.com/

💥 Libo-libong regalo para sa mga customer na umorder ng Dr HepoganGold sa livestream na ito
Buy 5 get 3; Buy 3 get 2; Buy 2 get 1 👇
Kunin ang iyong regalo dito: https://st1.drhepogangold2022.com/
------------
👉 Kontrolin ang antas ng hepatitis B virus sa isang ligtas na antas, bawasan ang panganib ng mga komplikasyon, pagbutihin ang paggana ng atay, pagpapanumbalik ng mga nasirang selula ng atay
✅ Mga oral tablet para sa talamak na hepatitis B Dr HepoganGold na may mahahalagang essences tulad ng Silymarin, Solanum procumbens, Phyllanthaceae, Curcumin:
- Sinusuportahan ang pagbawi ng function ng atay, pinipigilan ang hepatitis B virus mula sa pag-atake sa mga selula ng atay, pinoprotektahan ang atay mula sa loob mula sa alkohol at mga nakakapinsalang pagkain.
- Tumutulong upang mabilis na mapawi ang mga sintomas ng dilaw na balat, dilaw na mata, pagkapagod, pagduduwal, pananakit ng tiyan, pantal, pagkapagod ng katawan
✅ Precious essence 100% from nature, imported and applied the number 1 modern essence technology from Korea to increase absorption, absolute safety and high efficiency.
- Ang produkto ay madaling inumin, madaling matunaw, maginhawang dalhin kahit saan, anumang oras
- Uminom ng 1 tablet x 2 beses sa isang araw, 1 tablet sa umaga, 1 tablet sa gabi, 30 minuto pagkatapos kumain
✅ Ang produkto ay nasubok at na-certify ng Ministry of Health
-------------
👉 Get a quote here: https://st1.drhepogangold2022.com/

𝐇𝐞𝐩𝐚𝐭𝐢𝐭𝐢𝐬 𝐁
𝐊𝐞𝐲 𝐟𝐚𝐜𝐭𝐬
- Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease.
- The virus is most commonly transmitted from mother to child during birth and delivery, as well as through contact with blood or other body fluids during s*x with an infected partner, unsafe injections or exposures to sharp instruments.
- WHO estimates that 296 million people were living with chronic hepatitis B infection in 2019, with 1.5 million new infections each year.
- In 2019, hepatitis B resulted in an estimated 820 000 deaths, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer).
- Hepatitis B can be prevented by vaccines that are safe, available and effective.
𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰
Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). It is a major global health problem. It can cause chronic infection and puts people at high risk of death from cirrhosis and liver cancer.
A safe and effective vaccine that offers 98% to 100% protection against hepatitis B is available. Preventing hepatitis B infection averts the development of complications including chronic disease and liver cancer.
The burden of hepatitis B infection is highest in the WHO Western Pacific Region and the WHO African Region, where 116 million and 81 million people, respectively, are chronically infected. Sixty million people are infected in the WHO Eastern Mediterranean Region, 18 million in the WHO South-East Asia Region, 14 million in the WHO European Region and 5 million in the WHO Region of the Americas.
𝐓𝐫𝐚𝐧𝐬𝐦𝐢𝐬𝐬𝐢𝐨𝐧
In highly endemic areas, hepatitis B is most commonly spread from mother to child at birth (perinatal transmission) or through horizontal transmission (exposure to infected blood), especially from an infected child to an uninfected child during the first 5 years of life. The development of chronic infection is common in infants infected from their mothers or before the age of 5 years.
Hepatitis B is also spread by needlestick injury, tattooing, piercing and exposure to infected blood and body fluids, such as saliva and menstrual, vaginal and seminal fluids. Transmission of the virus may also occur through the reuse of contaminated needles and syringes or sharp objects either in health care settings, in the community or among persons who inject drugs. Sexual transmission is more prevalent in unvaccinated persons with multiple s*xual partners.
Hepatitis B infection acquired in adulthood leads to chronic hepatitis in less than 5% of cases, whereas infection in infancy and early childhood leads to chronic hepatitis in about 95% of cases. This is the basis for strengthening and prioritizing infant and childhood vaccination.
The hepatitis B virus can survive outside the body for at least 7 days. During this time, the virus can still cause infection if it enters the body of a person who is not protected by the vaccine. The incubation period of the hepatitis B virus ranges from 30 to 180 days. The virus may be detected within 30 to 60 days after infection and can persist and develop into chronic hepatitis B, especially when transmitted in infancy or childhood.
𝐒𝐲𝐦𝐩𝐭𝐨𝐦𝐬
Most people do not experience any symptoms when newly infected. However, some people have acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. People with acute hepatitis can develop acute liver failure, which can lead to death. Among the long-term complications of HBV infections, a subset of persons develops advanced liver diseases such as cirrhosis and hepatocellular carcinoma, which cause high morbidity and mortality.
HBV-HIV coinfection
About 1% of persons living with HBV infection (2.7 million people) are also infected with HIV. Conversely, the global prevalence of HBV infection in HIV-infected persons is 7.4%. Since 2015, WHO has recommended treatment for everyone diagnosed with HIV infection, regardless of the stage of disease. Tenofovir, which is included in the treatment combinations recommended as first-line therapy for HIV infection, is also active against HBV.
𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐢𝐬
It is not possible on clinical grounds to differentiate hepatitis B from hepatitis caused by other viral agents, hence laboratory confirmation of the diagnosis is essential. Several blood tests are available to diagnose and monitor people with hepatitis B. They can be used to distinguish acute and chronic infections. WHO recommends that all blood donations be tested for hepatitis B to ensure blood safety and avoid accidental transmission.
As of 2019, 30.4 million people (10.5% of all people estimated to be living with hepatitis B) were aware of their infection, while 6.6 million (22%) of the people diagnosed were on treatment. According to latest WHO estimates, the proportion of children under five years of age chronically infected with HBV dropped to just under 1% in 2019 down from around 5% in the pre-vaccine era ranging from the 1980s to the early 2000s.
In settings with high Hepatitis B surface antigen seroprevalence in the general population (defined as >2% or >5% HBsAg seroprevalence), WHO recommends that all adults have access to and be offered HBsAg testing with linkage to prevention and care and treatment services as needed.
𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭
There is no specific treatment for acute hepatitis B. Therefore, care is aimed at maintaining comfort and adequate nutritional balance, including replacement of fluids lost from vomiting and diarrhoea. Most important is the avoidance of unnecessary medications. Acetaminophen, paracetamol and medication against vomiting should be avoided.
Chronic hepatitis B infection can be treated with medicines, including oral antiviral agents. Treatment can slow the progression of cirrhosis, reduce incidence of liver cancer and improve long term survival. In 2021 WHO estimated that 12% to 25% of people with chronic hepatitis B infection will require treatment, depending on setting and eligibility criteria.
WHO recommends the use of oral treatments (tenofovir or entecavir) as the most potent drugs to suppress hepatitis B virus. Most people who start hepatitis B treatment must continue it for life.
In low-income settings, most people with liver cancer die within months of diagnosis. In high-income countries, patient present to hospital earlier in the course of the disease, and have access to surgery and chemotherapy which can prolong life for several months to a few years. Liver transplantation is sometimes used in people with cirrhosis or liver cancer in high-income countries, with varying success.
𝐏𝐫𝐞𝐯𝐞𝐧𝐭𝐢𝐨𝐧
WHO recommends that all infants receive the hepatitis B vaccine as soon as possible after birth, preferably within 24 hours, followed by 2 or 3 doses of hepatitis B vaccine at least 4 weeks apart to complete the vaccination series. Protection lasts at least 20 years and is probably lifelong. WHO does not recommend booster vaccinations for persons who have completed the 3-dose vaccination schedule.
In addition to infant vaccination, WHO recommends the use of antiviral prophylaxis for the prevention of hepatitis B transmission from mother-to-child. Implementation of blood safety strategies and safer s*x practices, including minimizing the number of partners and using barrier protective measures (condoms), also protect against transmission.
𝐖𝐇𝐎 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐞
In May 2016, the World Health Assembly adopted the first Global health sector strategy on viral hepatitis, 2016–2020. The strategy highlighted the critical role of universal health coverage and sets targets that align with those of the Sustainable Development Goals. The strategy proposed the elimination of viral hepatitis as a public health threat by 2030 (defined as a 90% reduction in new chronic infections and a 65% reduction in mortality, compared with the 2015 baseline), and included a roadmap towards elimination by implementing key prevention, diagnosis, treatment and community interventions strategies. In May 2022 the 75th World Health Assembly noted a new set of integrated global health sector strategies on HIV, viral hepatitis and s*xually transmitted infections for the period of 2022–2030. Based on these previous and now new strategies, a broad range of Member States have developed comprehensive national hepatitis programmes and elimination strategies guided by the global health sector strategy.
To support countries in achieving the global hepatitis elimination targets under the Sustainable Development Agenda 2030, WHO is working to:
raise awareness, promote partnerships and mobilize resources
formulate evidence-based policy and data for action
increase health equities within the hepatitis response
prevent transmission
scale up screening, care and treatment services.
WHO organizes the annual World Hepatitis Day campaign (as 1 of its 9 flagship annual health campaigns) to increase awareness and understanding of viral hepatitis. For World Hepatitis Day 2022, WHO focuses on the theme “Bringing hepatitis care closer to you” and calls for simplified service delivery of viral hepatitis services, bringing care closer to communities.
Link post: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
Support link: https://st1.drhepogangold2022.com